Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-5632
- Development stage
- Phase 2
- Lead developer
- Hengrui Pharmaceutical
- Administration
- Subcutaneous
01
Overview
HRS-5632 is an investigational drug developed for the treatment of lipoprotein disorders, which are characterized by abnormal metabolism of plasma lipoproteins and are a risk factor for atherosclerotic cardiovascular disease. The drug is currently in Phase 1 clinical trials, with studies evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity following single subcutaneous injection in healthy subjects. The precise mechanism of action has not been disclosed as of now. HRS-5632 is being developed by Hengrui Medicine (Jiangsu Hengrui Pharmaceuticals) and Fujian Suncadia Pharmaceuticals.
Beyond the preview
Go deeper on HRS-5632.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-5632.